Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

GB:0RC6 Stock Latest News

Company AnnouncementsPharmaMar Boosts Recurring Revenues on Zepzelca Growth Despite Lower One‑Off Income2d ago

Company AnnouncementsPharma Mar Names New Group CFO as Long-Serving Finance Chief Retires2d ago
Company AnnouncementsPharma Mar Continues September Share Buyback on Madrid Exchange1M ago
Company AnnouncementsPharma Mar Wins U.K. Approval for Zepzelca Combo in Small-Cell Lung Cancer1M ago
Company AnnouncementsPharma Mar Details August Share Buyback Transactions on Madrid Bourse1M ago

Pharma Mar Flags Planned Loss of Zepzelca Second-Line SCLC Indication

Company AnnouncementsPharma Mar Flags Planned Loss of Zepzelca Second-Line SCLC Indication2M ago

Company AnnouncementsPharma Mar Wins New Global Approvals for Zepzelca Lung Cancer Regimen2M ago

Company AnnouncementsPharma Mar Steps Up July Share Buybacks on Madrid Market2M ago

Company AnnouncementsPharma Mar Board Endorses 2026 Half-Year Financial Report3M ago
Company AnnouncementsPharmaMar Grows Recurring Revenue as EU Approval Boosts Zepzelca Outlook3M ago
Company AnnouncementsPharma Mar Board Approves 2026 Half-Year Financial Report3M ago
Company AnnouncementsPharma Mar Board Appointment Lapses, Governance Structure Unchanged3M ago

Pharma Mar Halts Liquidity Contract to Launch Share Buyback Program

Company AnnouncementsPharma Mar Halts Liquidity Contract to Launch Share Buyback Program3M ago

Company AnnouncementsPharma Mar Publishes Shareholder Presentation Ahead of 2026 AGM4M ago

Company AnnouncementsPharma Mar Shareholders Approve All Board Proposals at Ordinary Meeting4M ago

Company AnnouncementsPharma Mar Declares €1.00 Tax-Free Dividend from Share Premium Reserve4M ago
Company AnnouncementsPharma Mar Overhauls Board and Committees in Governance Refresh4M ago
Company AnnouncementsPharma Mar Launches €8 Million Share Buyback for Potential Corporate Deals4M ago
Company AnnouncementsPharmaMar’s Partner Merck Seeks Priority Approval in Japan for Zepzelca as First-Line SCLC Maintenance4M ago

Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan

The FlyPharma Mar price target lowered to EUR 100 from EUR 120 at Chardan4M ago

Company AnnouncementsEU clears PharmaMar’s Zepzelca combo for first‑line maintenance in aggressive lung cancer5M ago

Company AnnouncementsPharma Mar Calls 2026 Shareholders’ Meeting to Approve 2025 Results and Refresh Board5M ago